Liquid Biopsy from Urine
Resources from Novosanis® and nRichDX
nRichDX and Novosanis Collaboration Update
Watch the on-demand webinar
View the entire recorded webinar on 22 September 2022, or select webinar segments at the links below.
- Amit Arora, PhD, Sr. Scientist at DNA Genotek - Colli-Pee™ for urine collection and UAS™ for preservation (10 min.) View the segment.
- Nafiseh Jafari, PhD, Director of R&D at nRichDX - cfDNA and ctDNA extraction from urine using the Revolution Sample Prep System (10 min.) View the segment.
- KEYNOTE: Simpa Salami, PhD, MPH, Assistant Professor of Urology at the University of Michigan and Co-Director, Liquid Biopsy Core, Rogel Cancer Center - "Molecular Profiling of Urine for Prostate Cancer Diagnosis: Opportunities and Challenges" (20 min.) View the segment.
Colli-Pee UAS Combined with nRichDX Revolution System, a Promising Urinary Cell-free DNA Collection, Preservation and Extraction Workflow presented at the 2022 Association for Molecular Pathology (AMP) Meeting, 1-5 November 2022.
cfDNA and cfRNA extraction from urine samples presented at the 2022 Cancer Genomics Consortium (CGC) Meeting, 31 July - 3 August 2022.
cfDNA from First-Void Urine
cfRNA from First-Void Urine
Application Note from Novosanis and nRichDX on the collection, preservation, and extraction of cfDNA and ctDNA from first-void urine samples using the Novosanis Colli-Pee UAS™ device and the nRichDX Revolution Sample Prep System™
Preanalytical solutions for urine liquid biopsy applications
The Colli-Pee UAS device and the Revolution Sample Prep System work together to deliver unparalleled collection, preservation, yield, and purity of cfDNA, ctDNA, and other analytes from first-void urine samples.
Novosanis, a subsidiary of OraSure Technologies, Inc., is an innovator of first-void urine (FVU) urine sample collection with the Colli-Pee™ sample collection device family to improve the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee UAS™ devices provide non-invasive, self-collected, and volumetric sampling to standardize FVU collection, with a unique design to enable the immediate mixing of urine and preservative for FVU sample stability. Offering various sizes to capture a range of urine volumes for different application purposes, Novosanis is pioneering FVU sample collection as an alternative to invasive sampling -demonstrated by strong clinical research outcomes, patient preference and affordability.
The Colli-Pee™ is RUO-labeled in the U.S.
For Research Use Only. Not for use in diagnostic procedures.
nRichDX® Inc, based in California, is an emerging leader in liquid biopsy sample prep solutions that enable customers to extract much more analysis-ready cfDNA and ctDNA from blood and urine as compared to existing methods. The company’s patented Revolution Sample Prep System™ is the first and only high-yield, high-recovery, IVD-labeled liquid biopsy sample prep platform that can process a wide range of total volumes from 1 mL - 20 mL in a single extraction, without using schemes like pooling, bead recycling, and transfer steps other systems require. nRichDX solves one of precision medicine’s greatest problems – inaccurate or failed liquid biopsies due to a lack of target material. The Revolution System greatly enhances test sensitivity and enables testing for earlier detection, monitoring, timely treatment, and optimal patient outcomes.
*All trademarks are the property of their respective owners.